Brought to you by 
PhotoCure grants exclusive Hexvix rights to GE Healthcare; deal ends
26 Aug 2015
Executive Summary
PhotoCure ASA (drugs and devices for cancer) has licensed GE Healthcare exclusive worldwide rights (outside of the US and Nordic countries) to market and distribute the imaging agent Hexvix (hexaminolevulinate) for the diagnosis and monitoring of bladder cancer. GE also gets an option for marketing and distribution in the US.
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
Deal Status
- Terminated
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PhotoCure grants exclusive Hexvix rights to GE Healthcare; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice